For General Information, page-2410

I’m considering having an investment in both after reading up a bit on CAPR an hour ago. The CAPR market cap is 6 times ANPs (AUD 295 mill vs 45 mill) but they seem to be considerably more de-risked.

I’ve only read CAPR issued press releases though so don’t have the devil’s advocate side of the story, or any independent research. Just a bit reluctant to step into another biotech investment, given the wounds I’m carrying and the lesson learned that I’m investing (again) in a product (drugs) that I don’t really understand.